JP2001527517A - 血液、ウイルス性および細胞性疾患の治療組成物 - Google Patents
血液、ウイルス性および細胞性疾患の治療組成物Info
- Publication number
- JP2001527517A JP2001527517A JP50893198A JP50893198A JP2001527517A JP 2001527517 A JP2001527517 A JP 2001527517A JP 50893198 A JP50893198 A JP 50893198A JP 50893198 A JP50893198 A JP 50893198A JP 2001527517 A JP2001527517 A JP 2001527517A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- cells
- treatment
- cell
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. ウイルス感染細胞中、ウイルス産物の発現を誘発する誘発剤および該ウイ ルス産物に向け抗ウイルス活性を示す抗ウイルス剤を含むことを特徴とする製剤 組成物。 2. 該誘発剤が酪酸、イソプロピオン酸、2,2−もしくは3,3−ジメチルもしく はジエチル酪酸、酪酸エチルエステル、もしくはアミン、アミド、塩またはその 組み合せである請求項1記載の組成物。 3. 該抗ウイルス剤がインターフェロン、ヌクレオシド類似体、インテグラー ゼ阻害剤、ポリメラーゼ阻害剤または逆転写酵素阻害剤である請求項1記載の組 成物。 4. ウイルス細胞を死滅させる方法であって、遺伝子産物の発現を誘発するた めの誘発剤および該細胞中で発現した遺伝子産物の活性に比例して抗ウイルス活 性を示す抗ウイルス剤で該細胞を処理することを特徴とする方法。 5. 該ウイルス感染細胞がリンパ球である請求項4記載の方法。 6. 発現した遺伝子産物が増殖する細胞を抗ウイルス剤に感作する請求項4の 方法。 7. 該誘発剤がホルボール、酸化ホルボールエステル、セラミド、ブリオスタ チン、またはその組み合せである請求項4記載の方法。 8. 酪酸ジエチルもしくはジメチルおよび製剤的に受容可能な担体を含むこと を特徴とする製剤組成物。 9. ヒト疾患を治療する方法であって、実質的に無毒の化学物質組成物を、約 48時間より長い各パルス間隔で複数回のパルスにより患者に投与することを特 徴とする方法。 10. 該化学物資がプロピオン酸、酪酸、イソブチルアミド、α−アミノ−n −酪酸、フマール酸モノエチルエステル、酪酸ジメチルもしくはジエチル、乳酸 o−ベンゾイル、n−ジメチル酪酸グリシンアミド、乳酸o−ジメチル酪酸エス テル、ジエチル酪酸、イソ酪酸、イソプロピオン酸、トリフルオロ酪酸、酪酸エ チルエステル、メトキシ酢酸、フェニル酢酸、フェノキシ酢酸、フェニル酪酸、 エチル−フェニル酢酸、桂皮酸、ヒドロ桂皮酸、ジヒドロ桂皮酸、α−メチル− ヒドロ桂皮酸、3−フェニル酪酸、4−クロロ−2−フェノキシ 2−プロピオ ン酸、2−もしくは3−フェノキシプロピオン酸、2,2−ジメチル酪酸、トリブチ リン、トリフルオロ酪酸、チオフェノキシ酢酸、またはそのアルギニン、リジン もしくはコリン塩から成る群より選択される請求項9記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/687,670 | 1996-07-26 | ||
US08/687,671 US6197743B1 (en) | 1996-07-26 | 1996-07-26 | Compositions and methods for the treatment of viral disorders |
US08/687,671 | 1996-07-26 | ||
US08/687,670 US5939456A (en) | 1996-07-26 | 1996-07-26 | Pulsed administration of compositions for the treatment of blood disorders |
PCT/US1997/012818 WO1998004290A2 (en) | 1996-07-26 | 1997-07-28 | Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001527517A true JP2001527517A (ja) | 2001-12-25 |
JP2001527517A5 JP2001527517A5 (ja) | 2005-04-07 |
Family
ID=27104047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50893198A Pending JP2001527517A (ja) | 1996-07-26 | 1997-07-28 | 血液、ウイルス性および細胞性疾患の治療組成物 |
Country Status (5)
Country | Link |
---|---|
EP (4) | EP1886677A1 (ja) |
JP (1) | JP2001527517A (ja) |
AU (1) | AU3889197A (ja) |
CA (1) | CA2263675C (ja) |
WO (1) | WO1998004290A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008099730A1 (ja) * | 2007-02-14 | 2008-08-21 | Kaneka Corporation | 光学活性な2-(アロイルオキシ)プロピオン酸を用いたアミン化合物の製造方法 |
JP2011509253A (ja) * | 2008-01-08 | 2011-03-24 | アクセリア ファーマシューティカルズ | 抗菌ペプチド系に対する作動薬 |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7910624B1 (en) | 1995-03-03 | 2011-03-22 | The Trustees Of Boston University | Compositions for the treatment of blood disorders |
CA2324426A1 (en) | 1998-02-11 | 1999-08-19 | Douglas V. Faller | Compositions and methods for the treatment of cystic fibrosis |
AU2685399A (en) * | 1998-03-26 | 1999-10-18 | Julianna Lisziewicz | Method of rendering a human immunodeficiency virus population replication incompetent (in vivo) |
DE19839566C2 (de) | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
AU2622301A (en) * | 1999-11-05 | 2001-05-14 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
GB0008966D0 (en) | 2000-04-13 | 2000-05-31 | Imp College Innovations Ltd | Vectors for gene therapy |
AU4317500A (en) * | 2000-05-02 | 2001-11-12 | Lead Chemical Co., Ltd. | Antibiral compositions containing phorbol derivatives as the main active ingredient |
EP1372634B1 (de) | 2001-01-12 | 2009-11-11 | Biogen Idec International GmbH | Verwendung von fumarsäureamiden |
DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
CA2526586C (en) | 2003-09-09 | 2010-03-16 | Fumapharm Ag | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
GB0413702D0 (en) | 2004-06-18 | 2004-07-21 | Molmed Spa | Thymidine kinase |
EP2965751A1 (en) | 2004-10-08 | 2016-01-13 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
EP1915334A2 (en) * | 2005-07-07 | 2008-04-30 | Aditech Pharma AB | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US9873667B2 (en) | 2006-07-27 | 2018-01-23 | Emisphere Technologies Inc. | Arylsulfanyl compounds and compositions for delivering active agents |
EP2109608B1 (en) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
LT2653873T (lt) | 2007-02-08 | 2022-10-10 | Biogen Ma Inc. | Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti |
WO2008128299A1 (en) * | 2007-04-24 | 2008-10-30 | Murdoch Childrens Research Institute | Therapeutic protocol for treating hemoglobinopathy |
EP2276478A4 (en) * | 2008-04-11 | 2012-03-07 | Aids Res Alliance | METHOD FOR THE ADMINISTRATION OF PROSTRATIN AND STRUCTURAL ANALOGUE THEREOF |
EP3295936A1 (en) | 2009-01-09 | 2018-03-21 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
WO2011038224A1 (en) | 2009-09-24 | 2011-03-31 | Trustees Of Boston University | Methods for treating viral disorders |
WO2011072086A1 (en) * | 2009-12-08 | 2011-06-16 | Hemaquest Pharmaceuticals, Inc. | Methods and low dose regimens for treating red blood cell disorders |
US20110245154A1 (en) * | 2010-03-11 | 2011-10-06 | Hemaquest Pharmaceuticals, Inc. | Methods and Compositions for Treating Viral or Virally-Induced Conditions |
EP2555619A2 (de) | 2010-04-06 | 2013-02-13 | Bayer Intellectual Property GmbH | Verwendung der 4-phenylbuttersäure und/oder ihrer salze zur steigerung der stresstoleranz in pflanzen |
KR101293620B1 (ko) | 2011-08-19 | 2013-08-13 | 국립암센터 | 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도 |
CA2906580C (en) | 2013-03-14 | 2019-10-29 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
WO2015127450A1 (en) | 2014-02-24 | 2015-08-27 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
US20210338657A1 (en) * | 2018-08-06 | 2021-11-04 | Brigham Young University | Compositions and methods for treating iron overload |
SG11202113215UA (en) | 2019-05-31 | 2021-12-30 | Viracta Subsidiary Inc | Methods of treating virally associated cancers with histone deacetylase inhibitors |
CN113621577B (zh) * | 2021-08-05 | 2023-03-10 | 河南普诺易生物制品研究院有限公司 | 人源化hek293细胞系表达重组蛋白用培养基添加剂、重组乙肝疫苗、表达方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5813512A (ja) * | 1981-07-03 | 1983-01-26 | シャルル・シャニ | C↓1−c↓6カルボン酸と塩基性アミノ酸との反応生成物を含む薬剤 |
EP0324574A2 (en) * | 1988-01-13 | 1989-07-19 | Arizona Board Of Regents | Immunomodulating bryostatins |
JPH04501123A (ja) * | 1989-08-01 | 1992-02-27 | ザ ユニヴァーシティ オブ ミシガン | 脱水/水補給リポソームに被嚢されたペプチド/タンパク質の局所送達 |
WO1993004683A1 (en) * | 1991-09-12 | 1993-03-18 | American Cyanamid Company | Method of treating latent herpes viral infections |
WO1995010271A2 (en) * | 1993-10-12 | 1995-04-20 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders |
WO1995011699A1 (en) * | 1993-10-29 | 1995-05-04 | The Trustees Of Boston University | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
WO1996002244A1 (en) * | 1994-07-20 | 1996-02-01 | Agis Industries (1983) Ltd. | A topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US496525A (en) | 1893-05-02 | Eugene gillet de montmore | ||
US4470970A (en) * | 1981-07-02 | 1984-09-11 | Burzynski Stanislaw R | Purified antineoplaston fractions and methods of treating neoplastic disease |
US4704402A (en) | 1982-06-12 | 1987-11-03 | University Of Pittsburgh | Method of treating sickle cell anemia |
US4747825A (en) | 1984-06-29 | 1988-05-31 | Ferring Laboratories, Inc. | Apparatus and methodology for pulsed administration of growth promoting agents |
US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
US4948592A (en) | 1986-05-09 | 1990-08-14 | Alza Corporation | Pulsed drug delivery |
US4723958A (en) | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
US5025029A (en) | 1986-10-10 | 1991-06-18 | Children's Hospital Medical Center Of Northern California | Method for augmenting fetal hemoglobin |
US4822821A (en) | 1986-10-10 | 1989-04-18 | Children's Hospital Medical Center Of Northern California | Method for augmenting fetal hemoglobin |
US4965251A (en) | 1987-04-03 | 1990-10-23 | The Board Of Regents Of The University Of Washington | Pulse treatment of hemoglobinopathies with erythropoietin |
US5032507A (en) | 1987-11-13 | 1991-07-16 | The Salk Institute For Biological Studies | Potentiation of erythropoiesis |
US4997815A (en) | 1988-11-01 | 1991-03-05 | Children's Hospital Medical Center Of Northern California | Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin |
AU2804592A (en) * | 1991-10-21 | 1993-05-21 | Dvorit Samid | Compositions and methods for therapy and prevention of cancer, aids, and anemia |
US5403590A (en) | 1992-12-21 | 1995-04-04 | New England Deaconess Hospital Corporation | Method of pulsatile drug infusion |
US6011000A (en) * | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
-
1997
- 1997-07-28 EP EP07014281A patent/EP1886677A1/en not_active Withdrawn
- 1997-07-28 AU AU38891/97A patent/AU3889197A/en not_active Abandoned
- 1997-07-28 WO PCT/US1997/012818 patent/WO1998004290A2/en not_active Application Discontinuation
- 1997-07-28 EP EP97936153A patent/EP0969869A2/en not_active Ceased
- 1997-07-28 EP EP10184726A patent/EP2298350A3/en not_active Withdrawn
- 1997-07-28 EP EP05012584A patent/EP1611885A1/en not_active Withdrawn
- 1997-07-28 CA CA2263675A patent/CA2263675C/en not_active Expired - Fee Related
- 1997-07-28 JP JP50893198A patent/JP2001527517A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5813512A (ja) * | 1981-07-03 | 1983-01-26 | シャルル・シャニ | C↓1−c↓6カルボン酸と塩基性アミノ酸との反応生成物を含む薬剤 |
EP0324574A2 (en) * | 1988-01-13 | 1989-07-19 | Arizona Board Of Regents | Immunomodulating bryostatins |
JPH04501123A (ja) * | 1989-08-01 | 1992-02-27 | ザ ユニヴァーシティ オブ ミシガン | 脱水/水補給リポソームに被嚢されたペプチド/タンパク質の局所送達 |
WO1993004683A1 (en) * | 1991-09-12 | 1993-03-18 | American Cyanamid Company | Method of treating latent herpes viral infections |
WO1995010271A2 (en) * | 1993-10-12 | 1995-04-20 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders |
WO1995011699A1 (en) * | 1993-10-29 | 1995-05-04 | The Trustees Of Boston University | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
WO1996002244A1 (en) * | 1994-07-20 | 1996-02-01 | Agis Industries (1983) Ltd. | A topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus |
Non-Patent Citations (8)
Title |
---|
JPN6007004548, Proceedings. Annual Meeting of the American Associ, 19960423, Vol.37, p411−412 * |
JPN6009026838, New England Journal of Medicine, 1993, Vol.328,No.2, p81−86 * |
JPN6009026839, Blood, 1995, Vol.85,No.1, p43−49 * |
JPN6009026841, Blood, 1994, Vol.84,No.1, p339−343 * |
JPN6009026843, Blood, 1993, Vol.82,No.7, p2203−2209 * |
JPN6009026845, Blood, 1994, Vol.84,No.9, p3198−3204 * |
JPN6009026847, Blood, 1989, Vol.74,No.6, p1963−1971 * |
JPN6009026849, Blood, 1988, Vol.72,No.6, p1961−1967 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008099730A1 (ja) * | 2007-02-14 | 2008-08-21 | Kaneka Corporation | 光学活性な2-(アロイルオキシ)プロピオン酸を用いたアミン化合物の製造方法 |
JP2011509253A (ja) * | 2008-01-08 | 2011-03-24 | アクセリア ファーマシューティカルズ | 抗菌ペプチド系に対する作動薬 |
Also Published As
Publication number | Publication date |
---|---|
EP1611885A8 (en) | 2007-10-24 |
CA2263675A1 (en) | 1998-02-05 |
EP2298350A2 (en) | 2011-03-23 |
EP2298350A3 (en) | 2011-06-08 |
CA2263675C (en) | 2010-04-13 |
WO1998004290A3 (en) | 1998-08-13 |
EP0969869A2 (en) | 2000-01-12 |
WO1998004290A2 (en) | 1998-02-05 |
EP1886677A1 (en) | 2008-02-13 |
EP1611885A1 (en) | 2006-01-04 |
AU3889197A (en) | 1998-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001527517A (ja) | 血液、ウイルス性および細胞性疾患の治療組成物 | |
US6197743B1 (en) | Compositions and methods for the treatment of viral disorders | |
US6011000A (en) | Compositions for the treatment of blood disorders | |
ES2252519T3 (es) | Acido valproico para el tratamiento de cancer de mama, cancer de colon, cancer de cabeza y cuello, carcinoma de celulas pequeñas de pulmon y leucemia, en combinacion con radioterapia. | |
JP2021091690A (ja) | 急性骨髄性白血病(aml)のための新規併用治療 | |
US20090082444A1 (en) | Compositions for the Treatment of Blood Disorders | |
KR940002820B1 (ko) | Hiv 감염 관련 질병의 치료를 위한 약제 조성물 | |
AU2014343214B2 (en) | Methods of treating acute myeloid leukemia with a FLT3 mutation | |
ES2312884T3 (es) | Composiciones antivirales que comprenden derivados de acido fenilacetico. | |
WO1996027369A9 (en) | Compositions for the treatment of blood disorders | |
JP2008529966A (ja) | 遺伝病素因状態の抑制療法のためのヒストンデアセチラーゼ阻害剤の使用 | |
JP2018526460A (ja) | 急性骨髄性白血病の処置のためのダクチノマイシン組成物および方法 | |
Liu et al. | Regulation of S100A4 expression via the JAK2–STAT3 pathway in rhomboid-phenotype pulmonary arterial smooth muscle cells exposure to hypoxia | |
WO2017161307A1 (en) | Indole regulation of antigen presenting cells | |
Oberdörfer et al. | Role of IDO activation in anti-microbial defense in human native astrocytes | |
WO2017182981A1 (en) | Ppar agonist or lxr agonist for use in the treatment of systemic lupus erythematosus by modulation of lap activity | |
JP2006503871A (ja) | Amlの処置 | |
JP2020504164A (ja) | 急性骨髄性白血病の予防および処置 | |
AU2013332732A1 (en) | Treatment of viral and infectious diseases using an inhibitor of CBP/catenin | |
WO2022080249A1 (ja) | 炎症性腸疾患の予防又は改善剤 | |
JP4014330B2 (ja) | ウイルス感染防御剤 | |
JP2021533768A (ja) | 固形癌及び微生物感染を治療するための方法及び組成物 | |
US7910624B1 (en) | Compositions for the treatment of blood disorders | |
JP7505160B2 (ja) | ヒドロキシ尿素を含む炎症反応を阻害するための医薬組成物 | |
JP2020504163A (ja) | 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040728 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071106 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080205 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080324 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080507 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090609 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090908 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091026 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091209 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100803 |